Precision Nanoplatform for Renal Therapeutic Delivery
At NanoRenx Therapeutics, we are advancing an innovative kidney-targeted delivery platform built on ultrasmall, biocompatible nanoassemblies. Designed for systemic administration, our nanoplatform combines size-enabled renal access with experimentally validated receptor-mediated uptake into renal tubular and stromal cells. Our technology accommodates small-molecule drugs and therapeutic oligonucleotides, creating partnership opportunities with pharmaceutical and biotechnology companies.
Features
Ultrasmall Nanoarchitecture
Our ultrasmall, biocompatible nanoassemblies are engineered for systemic administration and size-enabled renal access, offering a distinctive approach to overcoming conventional barriers in kidney-targeted drug delivery.
Dual-Cell Targeting
Our platform leverages receptor-mediated uptake into renal tubular and stromal cells, enabling access to two important cellular populations involved in kidney disease and its progression.
Versatile Therapeutic Delivery
Designed to accommodate both small-molecule drugs and therapeutic oligonucleotides, our adaptable nanoplatform offers pharmaceutical partners opportunities to develop kidney-targeted formulations across multiple therapeutic modalities.
Preclinical Validation & Partnerships
Supported by encouraging preclinical renal biodistribution findings, NanoRenx seeks strategic collaborations with pharmaceutical and biotechnology companies to advance innovative kidney-targeted therapeutic delivery solutions.
About NanoRenx Therapeutics
NanoRenx Therapeutics is an emerging biotechnology company dedicated to overcoming a major challenge: the precise delivery of therapeutics to the kidneys. Our mission is to translate nanotechnology into a versatile renal delivery platform that expands the therapeutic potential of drug candidates. Combining expertise in nanomedicine, drug delivery, and renal biology, we seek strategic partnerships with pharmaceutical and biotechnology companies to advance next-generation treatments for kidney diseases.
Frequently Asked Questions
What is NanoRenx Therapeutics?
NanoRenx Therapeutics is an early-stage biotechnology company developing an innovative nanoplatform for kidney-targeted therapeutic delivery. Our mission is to enable pharmaceutical and biotechnology partners to deliver their therapeutic candidates more precisely to the kidneys using ultrasmall, biocompatible nanoassemblies.
How does your drug delivery platform work?
Our platform combines ultrasmall nanoarchitecture designed to facilitate renal access with experimentally validated receptor-mediated uptake into renal tubular cells and activated fibroblasts. Following systemic administration, our nanoassemblies are designed to deliver therapeutic payloads to these key renal cell populations.
Who do you collaborate with?
We seek strategic partnerships with pharmaceutical and biotechnology companies developing small-molecule drugs and oligonucleotide therapeutics. Our platform is designed to support the development of kidney-targeted formulations and expand therapeutic opportunities across renal diseases.
What are the benefits of targeted kidney drug delivery?
Targeted renal delivery has the potential to increase therapeutic exposure in kidney tissues while reducing unwanted distribution to other organs. Our nanoplatform is designed to address these challenges through size-enabled renal access and selective cellular uptake, with encouraging findings from preclinical studies.
Strategic Collaborations
NanoRenx Therapeutics seeks strategic partnerships with pharmaceutical and biotechnology companies developing innovative therapeutics for kidney diseases. Our versatile nanoplatform offers opportunities to integrate small-molecule drugs and therapeutic oligonucleotides into kidney-targeted delivery systems. Together, we aim to overcome renal delivery barriers and accelerate the development of next-generation therapies.
Let's talk!

Business Hours

Mon - Fri
-
Sat - Sun
Closed
Custom Address Details

Contact Us